Pharmacological evaluation of a novel 18F-benzamide with high uptake and specificity to melanotic tissues as a PET diagnostic agent for melanoma
dc.contributor.author | Berghofer, PJ | en_AU |
dc.contributor.author | Taylor, SR | en_AU |
dc.contributor.author | Ballantyne, P | en_AU |
dc.contributor.author | Pham, TQ | en_AU |
dc.contributor.author | Loc’h, C | en_AU |
dc.contributor.author | Wyatt, NA | en_AU |
dc.contributor.author | Nguyen, VH | en_AU |
dc.contributor.author | Denoyer, D | en_AU |
dc.contributor.author | Hicks, RJ | en_AU |
dc.contributor.author | Grégoire, MC | en_AU |
dc.contributor.author | Katsifis, A | en_AU |
dc.contributor.author | Greguric, ID | en_AU |
dc.date.accessioned | 2025-07-31T13:13:12Z | en_AU |
dc.date.available | 2025-07-31T13:13:12Z | en_AU |
dc.date.issued | 2013-05 | en_AU |
dc.date.statistics | 2025-05-15 | en_AU |
dc.description.abstract | With distinct increases in incidence and mortality of melanoma worldwide our objective was to prepare radiolabel and evaluate [18F]MEL054; an enticing novel melanin targeting PET radiopharmaceutical whose characteristics have been taken from our previously reported iodinated molecules [123I]MEL037 and [123I]MEL008. As the chemistry of [18F]MEL054 can be simply translated to an iodine based [131I]radiopharmaceutical this is our first phase in creating an effective diagnostic/therapeutic pair targeting metastatic melanoma. © Wiley | en_AU |
dc.identifier.articlenumber | S9 | en_AU |
dc.identifier.citation | Berghofer, P., Taylor, S. R., Ballantyne, P., Pham, T. Q., Loc’h, C., Wyatt, N., Nguyen, V. H., Denoyer, D., Hicks, R. J., Gregoire, M., Katsifis, A., & Greguric, I. (2013). Pharmacological evaluation of a novel 18F-benzamide with high uptake and specificity to melanotic tissues as a PET diagnostic agent for melanoma. Presentation to the 20th International Symposium on Radiopharmaceutical Sciences, 12-17 May 2013, Jeju, South Korea. In Journal of Labelled Compounds and Radiopharmaceuticals, 56(S1), S9. doi:10.1002/jlcr.3057 | en_AU |
dc.identifier.conferenceenddate | 2013-05-17 | en_AU |
dc.identifier.conferencename | 20th International Symposium on Radiopharmaceutical Sciences | en_AU |
dc.identifier.conferenceplace | Jeju, South Korea | en_AU |
dc.identifier.conferencestartdate | 2013-05-12 | en_AU |
dc.identifier.issue | S1 | en_AU |
dc.identifier.journaltitle | Journal of Labelled Compounds and Radiopharmaceuticals | en_AU |
dc.identifier.uri | https://apo.ansto.gov.au/handle/10238/16384 | en_AU |
dc.identifier.volume | 56 | en_AU |
dc.language.iso | en | en_AU |
dc.publisher | Wiley | en_AU |
dc.relation.uri | https://doi.org/10.1002/jlcr.3057 | en_AU |
dc.subject | Pharmacology | en_AU |
dc.subject | Fluorine 18 | en_AU |
dc.subject | Neoplasms | en_AU |
dc.subject | Positron computed tomography | en_AU |
dc.subject | Labelling | en_AU |
dc.subject | Diagnostic techniques | en_AU |
dc.subject | Radiopharmaceuticals | en_AU |
dc.subject | Chemistry | en_AU |
dc.subject | Iodine | en_AU |
dc.subject | Tumor cells | en_AU |
dc.title | Pharmacological evaluation of a novel 18F-benzamide with high uptake and specificity to melanotic tissues as a PET diagnostic agent for melanoma | en_AU |
dc.type | Conference Presentation | en_AU |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.63 KB
- Format:
- Item-specific license agreed upon to submission
- Description: